A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parellel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Comibayion with IVacaftor in Subjects Aged 12 years and Older with Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutaton

Grants and Contracts Details

StatusFinished
Effective start/end date6/16/15 → 5/30/17

Funding

  • Vertex Pharmaceuticals Inc: $36,258.00